While the drug is currently only available through compassionate use programs, expanded access programs and clinical trials, Gilead plans to distribute the drug to the general public if it receives FDA approval.
“Providing our existing supplies at no charge is the right thing to do, to facilitate access to patients as quickly as possible and in recognition of the public emergency posed by this pandemic,” Mr. O’Day wrote.
The drugmaker said it plans to produce more than 500,000 treatment courses by October and more than 1 million by the end of the year.
The 1.5 million doses it has produced so far could treat about 140,000 patients, according to Mr. O’Day. So far, remdesivir has been used on about 1,700 patients.
Read the full letter here.
More articles on pharmacy:
CVS, Walgreens, Rite Aid coronavirus response updates
Drugs needed to put patients on ventilators in short supply
US pushing unapproved drug from Japan to fight COVID-19
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
